Press release content from PR Newswire. The AP news staff was not involved in its creation.
Arthur J. Gallagher & Co. Acquires Terrier Claims Services, Inc. and MT Investigations, LLC
April 1, 2021 GMT
Arthur J. Gallagher & Co. Logo (PRNewsfoto/Arthur J. Gallagher & Co.)
ROLLING MEADOWS, Ill., April 1, 2021 /PRNewswire/ Arthur J. Gallagher & Co. today announced that its risk management services subsidiary, Gallagher Bassett Services, Inc. (GB), has acquired Pleasantville, NY-based Terrier Claims Services, Inc. (TCS) and its affiliate, MT Investigations, LLC. Terms of the transaction were not disclosed.
Founded in 1996, TCS is a full-service claims investigation firm dedicated exclusively to insurance defense, third-party administrators, defense attorneys and government agencies. The team conducts extensive field investigations, trial preparation and property adjusting services in New York, New Jersey, Pennsylvania and Connecticut, in addition to nationwide desktop investigatio
Press release content from Business Wire. The AP news staff was not involved in its creation.
Half of Consumers Say Their Spending Habits Have Changed Permanently Due to the Pandemic, According to a New AlixPartners Report
April 1, 2021 GMT
NEW YORK (BUSINESS WIRE) Apr 1, 2021
A new report released today by AlixPartners, the global consulting firm, finds that one in two consumers around the globe has had their consumption habits permanently changed due to effects of the COVID-19 pandemic which is just one of the findings from the firm’s ongoing, empirically-centered research into changing consumer priorities that has led AlixPartners also to announce today the launch of a new modelling approach that segments consumers by their pandemic-related anxieties.
Press release content from Business Wire. The AP news staff was not involved in its creation.
Energy Transfer and Centurion Pipeline to Provide Joint Tariff Crude Oil Service From Platteville and Cushing to Nederland
April 1, 2021 GMT
Energy Transfer LP (NYSE: ET) and
Centurion Pipeline L.P. (“Centurion”) announced today that they will post a joint tariff for crude oil transportation service from ET’s terminals in Platteville, Colorado and Cushing, Oklahoma to ET’s Nederland, Texas terminal.
ADVERTISEMENT
The joint tariff service utilizes existing ET and Centurion pipeline assets that will be linked together via new connections in Oklahoma. The joint tariff service is expected to commence service by June 1, 2021. The joint tariff service may also be expanded to include an origin point of Guernsey, Wyoming. For parties interested in becoming a committed shipper, please contact Misbah Tukdi at Misbah.tukdi@energytransfer.com or Scott Hutson at Scott Hutson@centurionpl.co
Press release content from Business Wire. The AP news staff was not involved in its creation.
Quidel Supports New NIH, CDC Public Health Initiative for At-home COVID-19 Testing
April 1, 2021 GMT
SAN DIEGO (BUSINESS WIRE) Mar 31, 2021
Quidel Corporation (NASDAQ: QDEL) (“Quidel”), a leading provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that it is partnering with the Centers for Disease Control and Prevention (CDC) and the National Institutes of Health (NIH) on an innovative community health initiative called “Say Yes! COVID Test” in Pitt County, North Carolina, and coming soon to Chattanooga/Hamilton County, Tennessee. Quidel is providing two million QuickVue® At-Home OTC COVID-19 Tests to be distributed to approximately 160,000 residents free of charge across the two communities. The study is designed to determine if access to at-home rapid antigen tests three times a week for one month ca
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
CytoDyn Files New Protocol with U.S. FDA for 4 Doses of Leronlimab for Critically Ill COVID-19 .
CytoDyn Inc.April 1, 2021 GMT
Trial commencement will be expedited by enrolling patients in Brazil, U.K., and Canada while immediate EUA requests are pursued in multiple countries
VANCOUVER, Washington, April 01, 2021 (GLOBE NEWSWIRE) CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company”), a late-stage biotechnology company developing Vyrologix™ (leronlimab-PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced today that after several weeks of discussions with the U.S. Food and Drug Administration (“FDA”) and analysis of CD12 trial data, and in particular the 82% survival results over placebo after two weeks of leronlimab treatment, with statistically significant p-value of 0.0233, the Company has filed a new protocol to extend tre